Helus Pharma Closes $50M Offering, Fuels Phase 3 Trial and Pipeline Development
HELP sits 39% above its 52-week low of $3.76.
Summary
Helus Pharma (Cybin Inc.) has closed its previously announced $50 million underwritten offering, selling 10,309,280 common shares at $4.85 each. This follows the initial offering announcement yesterday and its pricing earlier today. The $50 million in gross proceeds is critical for the clinical-stage company, providing essential funding for its HLP003 Phase 3 trial, HLP004, and HLP005 programs. While highly dilutive, this capital infusion secures the necessary runway for pipeline development. Phase 3 APPROACH data for HLP003 is expected in Q4 2026.
At the time of this announcement, HELP was trading at $5.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3M. The 52-week trading range was $3.76 to $9.83. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.